Kevin Feeley Sells 15,516 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 15,516 shares of the stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $92.18, for a total transaction of $1,430,264.88. Following the completion of the sale, the chief financial officer now directly owns 1,726 shares in the company, valued at approximately $159,102.68. The trade was a 89.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, March 26th, Kevin Feeley sold 8,746 shares of GeneDx stock. The stock was sold at an average price of $95.61, for a total transaction of $836,205.06.
• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total transaction of $362,565.79.
• On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The shares were sold at an average price of $90.05, for a total value of $36,200.10.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The stock was sold at an average price of $94.72, for a total value of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total value of $21,582.00.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $96.63 on Friday. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The stock has a market cap of $2.71 billion, a PE ratio of -49.30 and a beta of 1.93. The company’s fifty day moving average is $90.43 and its 200 day moving average is $78.11. GeneDx Holdings Corp. has a 52 week low of $8.63 and a 52 week high of $115.60.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million for the quarter, compared to the consensus estimate of $82.24 million. Research analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. The Goldman Sachs Group boosted their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen upped their target price on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, GeneDx currently has a consensus rating of “Moderate Buy” and a consensus price target of $72.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC raised its holdings in GeneDx by 22,194.3% during the 1st quarter. GAMMA Investing LLC now owns 38,792 shares of the company’s stock valued at $3,436,000 after buying an additional 38,618 shares during the last quarter. Wellington Management Group LLP bought a new position in shares of GeneDx during the fourth quarter valued at about $10,821,000. California State Teachers Retirement System boosted its holdings in shares of GeneDx by 13.3% during the fourth quarter. California State Teachers Retirement System now owns 11,384 shares of the company’s stock worth $875,000 after purchasing an additional 1,335 shares during the period. Polar Asset Management Partners Inc. bought a new stake in shares of GeneDx in the fourth quarter worth about $1,007,000. Finally, Palisades Investment Partners LLC purchased a new position in GeneDx during the 4th quarter valued at about $6,425,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.